US Patent

US9808431 — Immediate release oral guaifenesin solution

Method of Use · Assigned to Sovereign Pharmaceuticals LLC · Expires 2035-11-13 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an immediate release oral solution for guaifenesin that includes propylene glycol and glycerol as solvents to increase guaifenesin bioavailability.

USPTO Abstract

Disclosed is an immediate release solution for oral administration of guaifenesin and at least one additional drug. In addition to water the solution comprises as solvents propylene glycol and glycerol in a concentration which significantly increases the bioavailability of guaifenesin in the human body.

Drugs covered by this patent

Mucinex (guaifenesin) · Generic (multiple manufacturers)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2023`	—	Mucinex

Patent Metadata

Patent number: US9808431
Jurisdiction: US
Classification: Method of Use
Expires: 2035-11-13
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Sovereign Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.